Thu, May 15, 9:14 PM (59 days ago)
**Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue generated; the company remains in the clinical development stage. - **Net Loss:** $2,864,000, a decrease from $3,401,000 in Q1 2024. - **Cash Position:** $1,826,000 in cash, cash equivalents, and restricted cash as of March 31, 2025. - **Operating Expenses:** $3,089,000, including $1,304,000 in R&D and $1,785,000 in G&A. - **Net Loss Per Share:** $0.45, down from $0.75 in Q1 2024. **Cash Flow:** - **Operating Activities:** Net cash used was $1,631,000. - **Financing Activities:** Net cash provided was $3,086,000 from sales of common stock, short-term loans, and warrants exercise. **Quarterly Performance Discussion:** - **Operational Highlights:** Continued focus on NurOwn®, the proprietary cell therapy platform for neurodegenerative diseases. - **Clinical Trials:** Ongoing Phase 3b trial for ALS, with alignment on CMC aspects with the FDA. - **Funding:** Raised $3,086,000 through ATM offerings, short-term loans, and warrants exercise. - **Uncertainties:** Dependence on successful clinical trials, regulatory approvals, and additional funding. **Future Operations Impact:** - **Regulatory Pathway:** Continued engagement with the FDA for NurOwn® approval. - **Funding Needs:** Anticipates substantial additional financing for Phase 3b trials and commercialization. - **Market Risks:** Vulnerable to macroeconomic conditions, geopolitical risks, and market volatility. **Trends and Uncertainties:** - **Positive Trends:** Successful engagement with the FDA and progress in clinical trials. - **Uncertainties:** Dependence on external funding, regulatory approvals, and market conditions. **Conclusion:** Brainstorm Cell Therapeutics remains focused on advancing NurOwn® through clinical trials and regulatory pathways. The company faces significant financial challenges and uncertainties but continues to progress towards potential commercialization.